Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MWX401 in Healthy Participants and Mild Hypertension
NCT07803835Phase 1Recruiting
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MWX401 in essential hypertension (5 cohorts), sponsored by Shanghai Minwei Biotechnology Co., Ltd. Primary endpoint: Incidence and severity of treatment-emergent adverse events at 85 days. Started Mar 2026; status: recruiting.
02
Drugs
MWX401
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT07803835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803835.